In a report released today, Raju Prasad from William Blair maintained a Buy rating on Beam Therapeutics (BEAM). The company’s shares closed last Tuesday at $65.45.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 9.7% and a 45.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Beam Therapeutics is a Moderate Buy with an average price target of $109.40.
See today’s analyst top recommended stocks >>
Beam Therapeutics’ market cap is currently $4.01B and has a P/E ratio of -16.50. The company has a Price to Book ratio of 18.04.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
